Transdermal rivastigmine in the treatment of Alzheimer’s disease: current and future directions

References

• Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighhi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement 2007;3(3):186-91
   PubMed Web of Science ®Google Scholar
• Ferri CP, Prince M, Brayne C, et al. Global prevelance of dementia: a Delphi consensus study. Lancet 2005;366(9503):2112-17
   PubMed Web of Science ®Google Scholar
• Sloane PD, Zimmerman S, Suchindran C, et al. The public health impact of Alzheimer’s disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health 2002;23:13-31
   Google Scholar
• Patocka J, Jun D, Kuca K. Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer’s disease. Curr Drug Metab 2008;9(4):332-5
   PubMed Web of Science ®Google Scholar
• Sedky K, Nazir R, Joshi A, Lippmann S. Which psychotropic medications induce hepatotoxicity. Gen Hosp Psychiatry 2012;34(1):53-61
   Google Scholar
• Rafii MS. Update on Alzheimer’s disease therapeutics. Rev Recent Clin Trials 2013;8(2):1-9
   Google Scholar
• Singh G, Thomas SK, Arcona S, et al. Treatment persistency with rivastigmine and donepezil in a large state Medicare program. J Am Geriatr Soc 2005;53:1269-70
   PubMed Web of Science ®Google Scholar
• Bassil N, Grossberg GT. Novel regimens and delivery systems in the pharmacological treatment of Alzheimer’s Disease. CNS Drugs 2009;23(4):293-307
   Google Scholar
• Nordberg A, Ballard C, Bullock R, et al. A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer’s disease. Prim Care Companion CNS Disord 2013;15(2): pii: 12r01412
   PubMedGoogle Scholar
• Nordberg A, Darreh-Shori T, Peskind E, et al. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimer Res 2009;6(1):4-14
   PubMed Web of Science ®Google Scholar
• Kurz A, Farlow M, Lefevre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review. Int J Clin Pract 2009;63(5):799-805
   PubMed Web of Science ®Google Scholar
• Lefevre G, Sedek G, Jhee SS, et al. Pharmacokinetics and pharmacodynamics of the novel daily Rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer’s disease patients. Clin Pharmacol Ther 2008;83(1):106-14
   PubMed Web of Science ®Google Scholar
• Lefevre G, Sedek G, Huang HA, et al. Pharmacokinetics of a Rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol 2007;47:471-8
   PubMed Web of Science ®Google Scholar
• Winblad B, Grossberg G, Frolich L, et al. IDEAL: a 6-month, double, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007;69(Suppl 1):S14-22
   Google Scholar
• Winblad B, Cummins J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22:456-67
   PubMed Web of Science ®Google Scholar
• Cummings J, Froelich L, Black S, et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm2) in Alzheimer’s disease. Dement Geriatr Cogn Disord 2012;33:341-53
   PubMed Web of Science ®Google Scholar
• Grossberg G, Cummings J, Frolich L, et al. Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild to moderate Alzheimer’s disease. Am J Alzheimers Dis Other Demen 2013;28(6):583-91
   Google Scholar
• Farlow M, Grossberg G, Sadowsky C, et al. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer’s dementia. CNS Neurosci Ther 2013;19:745-52
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinsone’s disease. N Engl J Med 2004;351:2509-18
   PubMed Web of Science ®Google Scholar
• Emre M, Poewe W, De Deyn PP, et al. Long-term safety of rivastigmine in Parkinson disease dementia: an open-label, randomized study. Clin Neuropharmacol 2014;37(1):9-16
   PubMed Web of Science ®Google Scholar
• Birks J, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2009;2:CD001191
   PubMed Web of Science ®Google Scholar
• Rountree SD, Chan W, Pavlik VN, et al. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimer’s Research & Therapy 2009;1(2):1-7
   Google Scholar
• Wattmo C, Wallin AK, Londos E, Minthon L. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with Cholinesterase inhibitor treatment. Alzheimer Dis Assoc Disord 2011;25(1):63-72
   Google Scholar
• Gauthier S, Robillard A, Cohen S, et al. Real-life effectiveness and tolerability of the rivastigmine trasdermal patch in patients with mild-to-moderate Alzheimer’s disease: the EMBRACE study. Curr Med Res Opin 2013;29(8):989-1000
   PubMed Web of Science ®Google Scholar
• Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr Med Res Opin 2005;21(8):1317-27
   PubMed Web of Science ®Google Scholar
• Bhasin M, Rowan E, Edwards K, McKeith I. Cholinesterase inhibitors in Dementia with Lewy Bodies: a comparative analysis. Int J Geriatr Psychiatry 2007;22(9):890-5
   PubMed Web of Science ®Google Scholar
• Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment od Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging 2008;3(2):211-25
   PubMed Web of Science ®Google Scholar
• Gauthier S, Emre M, Farlow MR, et al. Strategies for continued successful treatment of Alzheimer’s disease: switching cholinesterase inhibitors. Curr Med Res Opin 2003;19:707-14
   PubMed Web of Science ®Google Scholar
• Dantoine T, Auriacombe S, Sarazin M, et al. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer’s disease who failed to benefit from previous cholinesterase inhibitor treatment. J Clin Pract 2006;60(1):110-18
   Google Scholar
• Auriacombe S, Pere JJ, Loria-Kanza Y, Vellas B. Efficacy and safety in patients with Alzheimer’s disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002;18(3):129-38
   PubMed Web of Science ®Google Scholar
• Yang z, Zhang Y, Wang Z, et al. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int J Pharm 2013;452:344-54
   PubMed Web of Science ®Google Scholar
• Singh B, Parasaik AK, Mielke MM, et al. Association of Mediterranean diet with mild cognitive impairment and Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis 2014;39(2):271-82
   PubMed Web of Science ®Google Scholar
• Coelho FG, Santos-Galduroz RF, Gobbi S, Stella F. Systematized physical activity and cognitive performance in elderly with Alzheimer’s dementia: a systematic review. Rev Bras Psiquiatr 2009;31(2):163-70
   Google Scholar